Vosoritide for the Treatment of Achondroplasia

Authors

  • Teerapat Jintanatham Faculty of Pharmaceutical Sciences, Khon Kaen university
  • Wynne Nakthong Faculty of Pharmaceutical Sciences, Khon Kaen university
  • Chernporn Navanukraw Faculty of Pharmaceutical Sciences, Khon Kaen university
  • Kitiwan Vipulakorn Faculty of Medicine, Khon Kaen University
  • Theera Rittirod Faculty of Pharmaceutical Sciences, Khon Kaen university

Keywords:

Vosoritide, Achondroplasia

Abstract

Vosoritide is still an investigational dug, therefore not much information has been published, but essential information has been extracted and discussed in this article. According to our review, vosoritide has shown potential clinical outcome to treat achondroplasia without any known serious adverse effects.

References

DRUGBANK online. (2021). Vosoritide. [cited May 13, 2023] Available from: https://go.drugbank.com/drugs/DB11928?fbclid=IwAR2bF7mgbiGXzVU_00Zko2NHBn1nkqBL4JWUswwFR0UxnmW67cadWU9WqWI

Paton DM. Efficacy of vosoritide in the treatment of achondroplasia. Drugs Today (Barc). 2022;58(9):451-6. doi.org/10.1358/dot.2022.58.9.3422313

Beyond Achondroplasia. 2023. BMN-111 Mechanism of Action. [cited May 13, 2023] Available from: https://www.beyondachondroplasia.org/en/health/treatments/emergent-treatments/22-vosoritide?fbclid=IwAR0t99LfZbOpeZfzaQnCNso4Uk_2akncPaPFl0IMcqSEyGE0Ojbwa7hMQII

Duggan S. Vosoritide: first approval. Drugs 2021;81(17):2057-62. doi: 10.1007/s40265-021-01623-w.

Horton WA, Hall JG, Hecht JT. Achondroplasia. Lancet 2007;370(9582):162-172. doi: 10.1016/S0140-6736(07)61090-3.

Live life taller. 2021. What is Achondroplasia?. [cited May 13, 2023] Available from: https://www.livelifetaller.com/en/k/achondroplasia--21?fbclid=IwAR2SHlA_U9okq6aepUrmzZdH6yO5zyXxTB-yrkAbOFN_XrK_w4qg2IgViDk

Foreman PK, van Kessel F, van Hoorn R, van den Bosch J, Shediac R, Landis S. Birth prevalence of achondroplasia: A systematic literature review and meta-analysis. Am J Med Genet A 2020;182(10):2297-316. doi: 10.1002/ajmg.a.61787.

Ciszewski P. First Participant Dosed in Phase 2 Study of Vosoritide for Children with Achondroplasia. 2018. [cited May 24, 2023] Available from: https://checkrare.com/first-participant-dosed-in-phase-2-study-of-vosoritide-for-children-with-achondroplasia/

Chan ML, Qi Y, Larimore K, Cherukuri A, Seid L, Jayaram K, et al. Pharmacokinetics and Exposure-Response of Vosoritide in Children with Achondroplasia. Clin Pharmacokinet. 2022 ;61(2):263-280. doi: 10.1007/s40262-021-01059-1.

Savarirayan R, Tofts L, Irving M, Wilcox WR, Bacino CA, Hoover-Fong J, et al. Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study. Genet Med 2021;23:2443–7. doi.org/10.1038/s41436-021-01287-7

Drugs.com. (2023). Vosoritide Interactions. [cited June 16, 2023] Available from: https://www.drugs.com/drug-interactions/vosoritide.html

Downloads

Published

2023-08-24

How to Cite

1.
Jintanatham T, Nakthong W, Navanukraw C, Vipulakorn K, Rittirod T. Vosoritide for the Treatment of Achondroplasia. SRIMEDJ [Internet]. 2023 Aug. 24 [cited 2024 Nov. 5];38(4):420-4. Available from: https://li01.tci-thaijo.org/index.php/SRIMEDJ/article/view/259135

Issue

Vol. 38 No. 4 (2023): July - August

Section

Review Articles

License

Copyright (c) 2023 Srinagarind Medical Journal

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.